Leadership Change at Applied StemCell
Applied StemCell, a prominent name in genome engineering, has announced an exciting new chapter in its journey with the appointment of Dolores Baksh, Ph.D., as its Chief Executive Officer. This move comes as the company looks to expand its impact in the biotechnology field and accelerate innovation in cell and gene therapies.
Dr. Baksh's Vision for Applied StemCell
Speaking on her new role, Dr. Baksh expressed her enthusiasm. She emphasized the importance of the existing foundation laid by the company and shared her vision to enhance it further. Dr. Baksh stated, "I'm thrilled to join Applied StemCell at such a pivotal time. Ruby and the team have built a remarkable foundation of innovation, and I look forward to helping amplify that legacy by expanding our commercial reach, accelerating new product development, and forging partnerships that translate scientific breakthroughs into real-world impact."
Experience That Matters
Dr. Baksh brings over 20 years of leadership experience in the life sciences sector, specializing in cell and gene therapy manufacturing. Her background includes serving as the founding CEO of Hyperius Biotech and CEO of TAAV Biomanufacturing Solutions. During her career, she has significantly contributed to enabling technologies that not only enhance quality but also lower costs, which is crucial for improving patient access to advanced therapies.
A Strong Track Record in the Industry
Dr. Baksh's wealth of experience aligns perfectly with Applied StemCell's mission. The company is recognized for its proprietary TARGATT™ large knock-in technology, which has become a cornerstone in the development of tailored iPSC services and GMP-compliant cell lines. These innovations support vital research and therapeutic advancements, ensuring that Applied StemCell remains a trusted partner for biopharma companies.
Ongoing Commitment to Innovation
As Dr. Baksh steps into her role, former CEO Ruby Tsai, Ph.D., transitions to President and Chief Scientific Officer (CSO). Tsai will focus on guiding the company’s scientific strategy, ensuring that Applied StemCell continues to lead in innovation and quality. "Dolores brings exactly the kind of leadership we need to help scale Applied StemCell," Dr. Tsai remarked, emphasizing Baksh's capacity to drive high growth-oriented strategies.
About Applied StemCell
Founded in 2008, Applied StemCell has been at the forefront of gene editing technologies, enabling both academic and industry researchers to leverage the potential of induced pluripotent stem cells (iPSC). Their dedication to providing innovative genome engineering products and services ensures a clear intellectual property path to commercialization, making them a vital resource in the biotech landscape.
Contact Information
For media inquiries regarding this announcement, you may reach out to:
Pia Abola, Ph.D.
Director of Marketing
Applied StemCell
pia.abola@appliedstemcell.com
(408) 457-1312
Frequently Asked Questions
Who is the new CEO of Applied StemCell?
The new CEO is Dolores Baksh, Ph.D.
What is the focus of Applied StemCell?
Applied StemCell focuses on genome engineering, specifically in the development of cell and gene therapies.
What role will Ruby Tsai take on?
Ruby Tsai will serve as President and Chief Scientific Officer, guiding the scientific strategy of the company.
What technology is Applied StemCell known for?
Applied StemCell is known for its TARGATT™ large knock-in technology.
How can I contact Applied StemCell for media inquiries?
You can contact Pia Abola, Ph.D., via email at pia.abola@appliedstemcell.com or by phone at (408) 457-1312.
